Journal of cardiothoracic and vascular anesthesia
-
J. Cardiothorac. Vasc. Anesth. · Jan 2025
ReviewThe Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2024.
This special article is the 17th in an annual series for the Journal of Cardiothoracic and Vascular Anesthesia. The authors thank the editor in chief, Dr Kaplan, and the editorial board for the opportunity to continue this series, namely, the research highlights of the past year in the specialty of cardiothoracic and vascular anesthesiology.1 The major themes selected for 2024 are outlined in this introduction, and each highlight is reviewed in detail in the main article. The literature highlights in the specialty for 2024 begin with an update on perioperative rehabilitation and enhanced recovery in cardiothoracic surgery, with a focus on novel methods to best assess our patients in the preoperative period and the impact of implementing enhanced recovery care models on outcomes. ⋯ The fifth and final theme is an update on medical cardiology, with a focus on the outcomes of transcatheter management of regurgitant pathology, device management in heart failure, and new techniques in catheter ablation. The themes selected for this article are only a few of the diverse advances in the specialty during 2024. These highlights will inform the reader of key updates on a variety of topics, leading to improvement in perioperative outcomes for patients with cardiothoracic and vascular disease.
-
J. Cardiothorac. Vasc. Anesth. · Jan 2025
ReviewTwo Is Better than One: Aveir DR Leadless Pacemaker System with Dual-Chamber Pacing.
The Aveir DR dual-chamber Leadless Pacemaker system (Abbott Laboratories) was recently approved by the US Food and Drug Administration and is heralded to be the next generation of leadless pacemakers. Earlier generations of leadless pacemakers could only provide single-chamber right ventricular pacing, limiting their application to a small subset of patients in whom pacemaker therapy is indicated. ⋯ Although there have been prior documented experiences with the earlier generation of leadless pacemakers, the addition of a second leadless pacemaker to provide dual-chamber pacing adds new complexities. It is essential to understand what makes the Aveir DR system unique if an anesthesiologist were to come across one perioperatively.
-
J. Cardiothorac. Vasc. Anesth. · Jan 2025
Randomized Controlled TrialImpact of Dipyrone Administration on Postoperative Analgesia and Aspirin Effect in Patients Undergoing Coronary Artery Bypass Grafting: The Prospective Randomized DipASA Study.
The aim of the study was to investigate the impact of dipyrone administration on postoperative analgesia and acetylsalicylic acid (ASA) effect in patients undergoing coronary artery bypass grafting (CABG). ⋯ Dipyrone given after CABG seems safe and did not show any significant effect on platelet inhibition after ASA administration. Patients taking dipyrone postoperatively need significantly fewer additional coanalgesics. The ASA effect on platelet function should be checked at least once after surgery.
-
J. Cardiothorac. Vasc. Anesth. · Jan 2025
Comparative Study Observational StudyMitral Valve Repair in Patients with Chronic Kidney Disease: Long-Term Outcomes and Cardiac Remodeling.
Literature examining mitral valve repair (MVr) outcomes in patients with chronic kidney disease (CKD) is largely limited to short-term outcomes and percutaneous approaches. This study is the first to present long-term outcomes of mortality and morbidity with paired cardiac remodeling data from patients with CKD undergoing surgical MVr. ⋯ In patients with CKD undergoing MVr, eGFR is a predictor of decreased long-term survival and residual mitral regurgitation at 1 year. Further investigation is required to optimize postoperative outcomes in this patient population.
-
J. Cardiothorac. Vasc. Anesth. · Jan 2025
Comparative StudyRight Ventricular Function Following Sternotomy Versus a Less-Invasive Approach for Left Ventricular Assist Device Implant: Retrospective Cohort Study.
Durable left ventricular assist device (LVAD) implantation is traditionally performed via median sternotomy (MS). Less-invasive implantation may lower the incidence of postimplant right ventricular failure (RVF). Our primary objective was to determine whether less-invasive implantation reduces the odds of severe RVF compared to MS. ⋯ There was no reduction in the odds of severe RVF following LVAD implantation using less-invasive approaches versus MS. However, we found improved odds of 30-day survival in the less-invasive group. The underlying mechanism requires further investigation.